Clinical trials: Diseases of the Urinary System
Anemia, Chronic Kidney Disease
Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease
The primary objectives of this study are the following: 1. To test if the proportion of participants achieving a hemoglobin value greater than or equal to 10.0 g/dL at any time point after the first dose during the study is…
- Conditions
- Anemia, Chronic Kidney Disease, Kidney Disease
- Trial name
- NCT00436748
- Testing
- Darbepoetin Alfa
- Where
- 67 sites in United States, Belgium and 8 more
- Volunteers
- 116 people
- Sponsor
- Amgen
Trauma, Urinary Tract Infections
Does a Nitrofurazone Coated Bladder Catheter Reduce the Number of Urinary Tract Infections in Trauma
Urinary tract infections occurs in trauma. We investigate whether a nitrofurazone coated can reduce the number of urinary tract infections.
- Trial name
- NCT00192985
- Testing
- Nitrofuranzone coated bladder catheter
- Where
- Denmark
- Volunteers
- 216 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Carcinoma, Renal Cell
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
- Trial name
- NCT00835978
- Testing
- axitinib
- Where
- 65 sites in United States, Czechia and 4 more
- Volunteers
- 213 people
- Sponsor
- Pfizer
Urolithiasis, Urinary Tract Stones
Detection of Urinary Stones on ULDCT With Deep-learning Image Reconstruction Algorithm
Urolithiasis has an increasing incidence and prevalence worldwide, and some patients may have multiple recurrences. Because these stone-related episodes may lead to multiple diagnostic examinations requiring ionizing radiation…
- Conditions
- Urolithiasis, Urinary Tract Stones, Renal Colic, Deep Learning Reconstruction
- Trial name
- URO DLIR (NCT04490343)
- Testing
- Abdominopelvic low dose CT
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Metastatic Renal Cell Carcinoma, Metastatic Malignant Melanoma
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.
- Trial name
- NCT00625768
- Testing
- AS1409
- Where
- 4 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Antisoma Research
Chronic Renal Failure, Hypertension
Low Sodium Dialysate and Ambulatory Blood Pressure Measurement Parameters
End stage renal disease (ESRD) is related with increased cardiovascular mortality and morbidity. Hypertension (HT) is an important risk factor for cardiovascular disorder among hemodialysis (HD) patients.
- Trial name
- NCT02621450
- Testing
- standart dialysis, low sodium dialysis
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Yuzuncu Yil University
End Stage Renal Disease
Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China
This is a multicenter, randomized, open-label study to compare QoL in subjects with end-stage renal disease (ESRD) requiring PD or conventional in-center HD treatment.
- Trial name
- NCT02378350
- Testing
- Hemodialysis treatment (no specific device is defined), Peritoneal Dialysis treatment (no specific drug is defined)
- Where
- 21 sites in China
- Volunteers
- 668 people
- Sponsor
- Vantive Health LLC
Urinary Stone, Urinary Calculi
The Effect of the COVID-19 on Patient Preferences and Decision Making for Obstructive Urinary Stone Interventions
In this study, the investigators aim to evaluate the intervention preferences of patients with obstructive urinary stones who are suitable for operation during the COVID-19 pandemic.
- Conditions
- Urinary Stone, Urinary Calculi, Covid19
- Trial name
- NCT04924790
- Testing
- COVID-19 Pandemic
- Where
- Turkey (Türkiye)
- Volunteers
- 158 people
- Sponsor
- Ankara Training and Research Hospital
Renal Cell Carcinoma
A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma
A one-arm,open,multi-center study, to evaluate sorafenib (400mg twice daily ) as a adjuvant to prevent recurrence of RCC(renal cell carcinoma) patients after radical nephrectomy with a high-risk of recurring.
- Trial name
- AGuo (NCT01041482)
- Testing
- sorafenib
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Chinese Academy of Medical Sciences
Disorder of Transplanted Kidney, Proteinuria
Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients
The study 'Safety and Efficacy of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients' is designed to assess the effects of paricalcitol in kidney transplant recipients with proteinuria.
- Conditions
- Disorder of Transplanted Kidney, Proteinuria, Albuminuria
- Trial name
- NCT01436747
- Testing
- Paricalcitol
- Where
- Slovenia
- Volunteers
- 168 people
- Sponsor
- University Medical Centre Ljubljana
Bladder Cancer
Study of Tumour Focused Radiotherapy for Bladder Cancer
Bladder cancer is the seventh most common cancer in the UK, with 10,399 new cases diagnosed in 2011. In a quarter of these cases the cancer has infiltrated the muscular wall of the bladder (muscle invasive) and is life…
- Trial name
- RAIDER (NCT02447549)
- Testing
- WBRT, SART, DART
- Where
- 49 sites in Australia, New Zealand and 1 more
- Volunteers
- 345 people
- Sponsor
- Institute of Cancer Research, United Kingdom
End Stage Renal Disease, Catheter Infection
AUSTrian Randomized Interventional Study on Dialysis Accesses
Patients with diagnosed end stage renal disease and indication for chronic dialysis rely on a well-functioning access for dialysis.
- Conditions
- End Stage Renal Disease, Catheter Infection, Shunt Malfunction
- Trial name
- AUSTRIA (NCT03764358)
- Testing
- Arteriovenous Fistula, Tunneled Cuffed Catheter
- Where
- Austria
- Volunteers
- 220 people
- Sponsor
- Medical University of Vienna
Bladder Cancer
A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether lapatinib ditosylate is more effective than a placebo in killing tumor cells.
- Trial name
- LaMB (NCT00949455)
- Testing
- lapatinib ditosylate
- Where
- 27 sites in United Kingdom
- Volunteers
- 204 people
- Sponsor
- Queen Mary University of London
Bladder Cancer
A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer
This study is to verify the short-term efficacy and long-term prognosis of thulium laser resection compared with conventional transurethral resection of non-muscular invasive bladder cancer.
- Trial name
- NCT02951078
- Testing
- Thulium Laser en Bloc Resection of bladder tumor, Electrical transurethral resection of bladder tumor
- Volunteers
- 172 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Critical Illness, COVID-19 Pneumonia
Acute Kidney Injury in Coronavirus Disease-19 (COVID-19) Patients Admitted to the Intensive Care Unit (ICU)
The aim of this study is to evaluate the rate and outcomes of COVID-19 associated acute kidney injury (AKI) and use of kidney replacement therapy (KRT) in critically ill COVID-19 patients in ICUs in several large hospitals in…
- Conditions
- Critical Illness, COVID-19 Pneumonia, Acute Kidney Injury
- Trial name
- COVID-AKI-B (NCT04997915)
- Testing
- Observational study exploring the epidemiology and outcomes of AKI in critical COVID-19 patients admitted to the ICU
- Where
- 9 sites in Belgium
- Volunteers
- 1,286 people
- Sponsor
- University Hospital, Ghent
Overactive Bladder (OAB)
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
The purpose of this study is to descriptively evaluate the persistence among adults treated with mirabegron or antimuscarinics in Australia, South Korea and Taiwan.
- Trial name
- NCT03602508
- Testing
- mirabegron, solifenacin, darifenacin
- Where
- 2 sites in Australia, South Korea
- Volunteers
- 5,589 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Chronic Kidney Disease
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
The purpose of the present study is to investigate the association between the accumulation of advanced glycation end-products (AGE) and adverse outcomes (e.g.
- Trial name
- AGED (NCT02878317)
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- University of Nottingham
Urologic Neoplasms, Metastatic Bladder Cancer
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled…
- Conditions
- Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
- Trial name
- NCT01454089
- Testing
- OGX-427 600 mg, OGX-427 1000 mg, Gemcitabine
- Where
- 55 sites in United States, Canada and 5 more
- Volunteers
- 183 people
- Sponsor
- Achieve Life Sciences
Renal Insufficiency, Chronic
Impact of Physical Activity on Patients With Chronic Kidney Disease Not Receiving Dialysis Followed in the TIRCEL Network. An Exposed / Unexposed Study (PHYSALYS)
PHYSALYS is an observational multicenter study. It's an analytical study comparing 2 groups: patients exposed to physical activity and unexposed.
- Trial name
- PHYSALYS (NCT02818010)
- Testing
- Global Physical Activity Questionnaire
- Volunteers
- 259 people
- Sponsor
- Hospices Civils de Lyon
Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug delivery system, in combination with nivolumab is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are scheduled for…
- Conditions
- Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A, Bladder Cancer TNM Staging Primary Tumor (T) T2B, Bladder Cancer TNM Staging Primary Tumor (T) T3
- Trial name
- NCT03518320
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200, Nivolumab Injection [Opdivo]
- Where
- 6 sites in United States
- Volunteers
- 13 people
- Sponsor
- Taris Biomedical LLC